1983983-41-0
1983983-41-0
Chemical Structure
Avotaciclib
Synonym(s): BEY1107
- CAS No.: 1983983-41-0
- Formula:C13H11N7O
- Molecular Weight:281.27
IUPAC Name: 2,6-bis(2-aminopyrimidin-4-yl)pyridin-3-ol
InChIKey: VFVAQKKPFOPZEA-UHFFFAOYSA-N
SMILES: OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3
Biological Activity: Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Avotaciclib | 99.72% | Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.
- [2]. Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17(2): 100900.
Keywords
